Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 11.5% in March

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 45,300 shares, a decline of 11.5% from the March 15th total of 51,200 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 54,600 shares, the days-to-cover ratio is currently 0.8 days.

Alzamend Neuro Stock Down 12.8 %

Shares of NASDAQ:ALZN traded down $0.11 during midday trading on Monday, reaching $0.74. The company had a trading volume of 114,685 shares, compared to its average volume of 54,053. The business’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.36. The stock has a market cap of $5.09 million, a PE ratio of -0.75 and a beta of 0.02. Alzamend Neuro has a 1-year low of $0.74 and a 1-year high of $11.91.

Hedge Funds Weigh In On Alzamend Neuro

A number of institutional investors have recently bought and sold shares of ALZN. Bank of America Corp DE bought a new stake in Alzamend Neuro in the first quarter valued at approximately $35,000. Geode Capital Management LLC raised its stake in Alzamend Neuro by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 563,660 shares of the company’s stock valued at $318,000 after buying an additional 37,910 shares during the period. Renaissance Technologies LLC bought a new stake in Alzamend Neuro in the fourth quarter valued at approximately $28,000. Charles Schwab Investment Management Inc. bought a new stake in Alzamend Neuro in the fourth quarter valued at approximately $30,000. Finally, HRT Financial LP bought a new stake in Alzamend Neuro in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.